Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
09 janv. 2023 16h30 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
05 déc. 2022 07h02 HE
|
Nkarta, Inc.
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle...
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
02 déc. 2022 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
09 nov. 2022 16h02 HE
|
Nkarta, Inc.
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019...
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
07 nov. 2022 08h52 HE
|
Nkarta, Inc.
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of...
Nkarta to Participate at Upcoming Investor Conferences
02 nov. 2022 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
11 août 2022 16h02 HE
|
Nkarta, Inc.
Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company’s platform for...
Nkarta Announces Key Senior Leadership Team Appointments
25 juil. 2022 16h31 HE
|
Nkarta, Inc.
Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to support rapid development of allogeneic,...
Nkarta to Participate at Upcoming Investor Conference
31 mai 2022 07h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
16 mai 2022 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...